{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T04:12:43Z","timestamp":1750824763034,"version":"3.41.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research","doi-asserted-by":"publisher","award":["9552"],"award-info":[{"award-number":["9552"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejps.2017.08.009","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T07:45:17Z","timestamp":1502783117000},"page":"253-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Model based population PK-PD analysis of furosemide for BP lowering effect: A comparative study in primary and secondary hypertension"],"prefix":"10.1016","volume":"109","author":[{"given":"Mahendra","family":"Shukla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moustafa M.A.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhisheak","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kashif","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawahar","family":"Lal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.08.009_bb1000","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00560456","article-title":"Distribution, elimination and natriuretic effect of furosemide in patients with severe arterial hypertension","volume":"14","author":"Andreasen","year":"1978","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.08.009_bb0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/01.HYP.1.4.347","article-title":"Serial renin-angiotensin studies in spontaneously hypertensive and Wistar-Kyoto normotensive rats. Transition from normal- to high-renin status during the established phase of spontaneous hypertension","volume":"1","author":"Bagby","year":"1979","journal-title":"Hypertension"},{"key":"10.1016\/j.ejps.2017.08.009_bb1010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2125.2001.01320.x","article-title":"Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure","volume":"51","author":"Brynne","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.08.009_bb0010","doi-asserted-by":"crossref","first-page":"E544","DOI":"10.1208\/aapsj070355","article-title":"Pharmacokinetics\/pharmacodynamics and the stages of drug development: role of modeling and simulation","volume":"7","author":"Chien","year":"2005","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2017.08.009_bb0015","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ejps.2017.08.009_bb0020","series-title":"Pocket Companion to Brenner and Rector's the Kidney","first-page":"546","article-title":"Diuretics","author":"Clarkson","year":"2011"},{"key":"10.1016\/j.ejps.2017.08.009_bb0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.CIR.36.1.125","article-title":"Antihypertensive properties of furosemide","volume":"36","author":"Davidov","year":"1967","journal-title":"Circulation"},{"key":"10.1016\/j.ejps.2017.08.009_bb0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of four basic models of indirect pharmacodynamic responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2017.08.009_bb0035","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200241140-00002","article-title":"Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock","volume":"41","author":"De Paepe","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.08.009_bb0040","first-page":"83","article-title":"Creatinine determination according to Jaffe-what does it stand for?","volume":"4","author":"Delanghe","year":"2011","journal-title":"NDT Plus"},{"key":"10.1016\/j.ejps.2017.08.009_bb0045","first-page":"143","article-title":"Studies on vascular permeability in hypertension: action of anthocyanosides","volume":"4","author":"Detre","year":"1986","journal-title":"Clin. Physiol. Biochem."},{"key":"10.1016\/j.ejps.2017.08.009_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0008-6363(98)00076-5","article-title":"Rat models of hypertension, cardiac hypertrophy and failure","volume":"39","author":"Doggrell","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejps.2017.08.009_bb0055","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.129171","article-title":"Thiazide effects and adverse effects","volume":"54","author":"Ellison","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ejps.2017.08.009_bb0060","first-page":"105","article-title":"Log-transformation and its implications for data analysis","volume":"26","author":"Feng","year":"2014","journal-title":"Shanghai Arch. Psychiatry"},{"key":"10.1016\/j.ejps.2017.08.009_bb0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00092-12","article-title":"Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents","volume":"26","author":"Gonzalez","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejps.2017.08.009_bb0070","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/bdd.2510030408","article-title":"Dose-dependent pharmacokinetics of furosemide in the rat","volume":"3","author":"Hammarlund","year":"1982","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2017.08.009_bb0075","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0022-3565(25)21252-6","article-title":"Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling","volume":"233","author":"Hammarlund","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2017.08.009_bb0080","first-page":"565","article-title":"Changes in vascular permeability in stroke-prone spontaneously hypertensive rats studied with peroxidase as a tracer","volume":"25","author":"Hazama","year":"1975","journal-title":"Acta Pathol. Jpn."},{"key":"10.1016\/j.ejps.2017.08.009_bb0085","first-page":"1037","article-title":"Small artery structure and function in hypertension","volume":"14","author":"Heagerty","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ejps.2017.08.009_bb0090","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/j.1523-1755.2004.00627.x","article-title":"Cyclosporine a attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression","volume":"65","author":"Hocherl","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejps.2017.08.009_bb0095","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-198106060-00002","article-title":"Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models","volume":"6","author":"Holford","year":"1981","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.08.009_bb0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0163-7258(82)90051-1","article-title":"Kinetics of pharmacologic response","volume":"16","author":"Holford","year":"1982","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.08.009_bb0105","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.juro.2006.11.040","article-title":"Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis","volume":"177","author":"Huen","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.ejps.2017.08.009_bb1005","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/000331977602701004","article-title":"Furosemide and plasma renin activity in essential hypertension","volume":"27","author":"Hutcheon","year":"1976","journal-title":"Angiology"},{"key":"10.1016\/j.ejps.2017.08.009_bb0110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ejps.2017.08.009_bb0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/bdd.2510150302","article-title":"Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats","volume":"15","author":"Jang","year":"1994","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2017.08.009_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharep.2017.01.006","article-title":"Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions","author":"Kodati","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejps.2017.08.009_bb0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/138920006774832578","article-title":"Tissue distribution and pharmacodynamics: a complicated relationship","volume":"7","author":"Lin","year":"2006","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2017.08.009_bb0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2133\/dmpk.24.16","article-title":"Scaling pharmacodynamics from in vitro and preclinical animal studies to humans","volume":"24","author":"Mager","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.08.009_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11906-016-0636-7","article-title":"Loop diuretics in the treatment of hypertension","volume":"18","author":"Malha","year":"2016","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejps.2017.08.009_bb0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08037050701461084","article-title":"2007 ESH-ESC guidelines for the management of arterial hypertension-the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC)","volume":"16","author":"Mancia","year":"2007","journal-title":"Blood Press."},{"key":"10.1016\/j.ejps.2017.08.009_bb0145","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertensionThe task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejps.2017.08.009_bb0150","article-title":"Basic concepts in population modeling, simulation, and model-based drug development\u2014part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT: Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2017.08.009_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075906","article-title":"Increased renal iron accumulation in hypertensive nephropathy of salt-loaded hypertensive rats","volume":"8","author":"Naito","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2017.08.009_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MNH.0b013e3283360a46","article-title":"NKCC1 and hypertension: a novel therapeutic target involved in the regulation of vascular tone and renal function","volume":"19","author":"Orlov","year":"2010","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ejps.2017.08.009_bb0165","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1980.tb05842.x","article-title":"Kinetic disposition and diuretic effect of frusemide in acute pulmonary oedema","volume":"9","author":"Perez","year":"1980","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.08.009_bb0170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0008-6363(98)00077-7","article-title":"Lessons from rat models of hypertensionfrom Goldblatt to genetic engineering","volume":"39","author":"Pinto","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejps.2017.08.009_bb0175","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/BF01068420","article-title":"The use of Weibull distribution to describe the in vivo absorption kinetics","volume":"15","author":"Piotrovskii","year":"1987","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2017.08.009_bb0180","first-page":"381","article-title":"Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (part I)","volume":"18","author":"Ponto","year":"1990","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.08.009_bb0185","series-title":"Capillary Fluid Exchange: Regulation, Functions, and Pathology","article-title":"Pathophysiology of edema formation","author":"Scallan","year":"2010"},{"key":"10.1016\/j.ejps.2017.08.009_bb0190","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14656566.2014.879117","article-title":"Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents","volume":"15","author":"Tamargo","year":"2014","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ejps.2017.08.009_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097391","article-title":"Reference values for clinical laboratory parameters in young adults in Maputo, Mozambique","volume":"9","author":"Tembe","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2017.08.009_bb0200","first-page":"482","article-title":"Furosemide capsules in the treatment of hypertension or heart failure in the elderly in general practice","volume":"110","author":"Terland","year":"1990","journal-title":"Tidsskr. Nor. Laegeforen."},{"key":"10.1016\/j.ejps.2017.08.009_bb0205","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1365-2885.2002.00442.x","article-title":"Free drug fraction vs. free drug concentration: a matter of frequent confusion","volume":"25","author":"Toutain","year":"2002","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.08.009_bb0210","article-title":"Basic concepts in population modeling, simulation, and model-based drug development: part 3\u2014introduction to Pharmacodynamic modeling methods","volume":"3","author":"Upton","year":"2014","journal-title":"CPT: Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2017.08.009_bb0215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/bdd.1874","article-title":"Population-based meta-analysis of furosemide pharmacokinetics","volume":"35","author":"Van Wart","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2017.08.009_bb0220","first-page":"H1842","article-title":"Renal function contributes to antihypertensive effect of vasopressin in DOCA-salt but not spontaneous hypertension","volume":"267","author":"Wang","year":"1994","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.ejps.2017.08.009_bb0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00498254.2013.809616","article-title":"Pharmacokinetics of drugs in spontaneously or secondary hypertensive rats","volume":"44","author":"Yang","year":"2014","journal-title":"Xenobiotica"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717304529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717304529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T22:52:52Z","timestamp":1750805572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717304529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":48,"alternative-id":["S0928098717304529"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.08.009","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Model based population PK-PD analysis of furosemide for BP lowering effect: A comparative study in primary and secondary hypertension","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}